HOME  | CONTACT  | PATIENT LOGIN  | CLINIC LOGIN  | FAQ
  • PATIENTS &
    HEALTHY VOLUNTEERS
  • INVESTIGATORS
  • CROS / SPONSORS
  • CAREERS
  • TRIAL ALERTS

TRIALS SEARCH
      
  • HEALTH NEWS

  • RSS FEEDS

  • ABOUT TRIALS

  • LINK TO US


View Clinical Trial (Medical Research Study)


A Pilot Study to Evaluate the Role of Cyclooxygenase Pathway in Radiation Therapy and Chemoradiation Therapy Induced Mucositis in Head and Neck Cancer Patients

Signup
Browse Studies

City:   Burlington
State:   Vermont
Zip Code:   05401
Conditions:   Cancer of the Head and Neck - Radiotherapy
Purpose:   This study will evaluate the role of cyclooxygenase pathways in radiation-induced and chemoradiation-induced mucositis.
Study Summary:   Oral mucositis is a significant toxicity of radiation therapy and chemoradiation therapy in head and neck cancer patients. However the mechanisms that induce such mucositis are not completely understood. Previous work evaluating mucositis in bone marrow transplant patients has suggested that prostaglandin levels may be associated with the appearance of mucositis. The present study will measure the levels in saliva of the prostaglandins PGE2 and PGI2 before, during, immediately after, and several weeks after radiotherapy for head and neck cancer. These salivary levels will be correlated with clinical observation of mucositis and patient reporting of pain levels. Improved understanding of the mechanism of mucositis may lead to the development of more effective targeted agents to prevent this problem.
Criteria:   Inclusion Criteria: - Histologically proven locoregional Stage 4 squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx - Receiving radiation therapy or chemoradiation therapy to the oropharynx - Older than 18 years old - ECOG performance status of 0-2 - Life expectancy greater than 2 months - Signed informed consent Exclusion Criteria: - Previous chemotherapy for this malignancy - Previous radiotherapy to the head and neck - Other cancer diagnosis within the last 5 years except for non-melanoma skin cancer or non-metastatic prostate cancer - Patient taking NSAIDs
NCT ID:   NCT01252498
Primary Contact:   Principal Investigator
Steven M Grunberg, MD
University of Vermont/Fletcher Allen Health Care

Steven M Grunberg, MD
Phone: 802-847-8400
Email: Steven.Grunberg@uvm.edu
Backup Contact:   Email: Nathan.Adams@vtmednet.org
Nathan B Adams, MD
Phone: 802-847-8400
Location Contact:   Burlington, Vermont 05401
United States

Steven M Grunberg, MD
Phone: 802-847-8400
Email: Steven.Grunberg@uvm.edu

Site Status: Recruiting

Data Source:   ClinicalTrials.gov
Date Processed:   June 17, 2013
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"
First Name:  
Last Name:  
Email Address:  
Confirm Email:    
Daytime Phone (eg. 555-555-5555):  
City:  
State:
Zip Code:    
Best Time to Call:  
Questions/Comments:  
  • NEARBY STUDIES

Within 25 Miles

COPD (Emphysema and Chronic Bronchitis) - South Burlington VT

Within 50 Miles

Within 100 Miles

 
Clinical Connections Home | Investigators | CROs / Sponsors | Clinical Trials Notification | Search Clinical Trials | About Clinical Trials | Links | Terms And Conditions | Sitemap | Suggestions / Feedback
© 1998-2013 | All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.

ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.